Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:131-40.

Slides:

Advertisements

Similar presentations

Rational, Trial Design, and Results of the ADAGIO Delayed Start Trial C. Warren Olanow, MD, FRCPC Henry P. and Georgette Goldschmidt Professor Chairman.

Advertisements

Slides courtesy of Matt Hall Nottingham University Hospitals February 2011 Slides courtesy of Matt Hall Nottingham University Hospitals February 2011 Slides.

Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,

Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.

Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis NEJM, Jan 2014, M Graham-Brown 28/05/14.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

HYPERTENSION in ADPKD Sabine Karam M.D.. Introduction  ADPKD is the most common life-threatening single-gene disease  It affects over 12 million people.

Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.

Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

Randomized, double-blind, multicenter, controlled trial.

0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.

1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.

Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.

Impact of early surgery vs conventional treatment for infective endocarditis on mortality and embolic events: data from EASE trial Prospective RCT ( );

Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery Nancy A. Nussmeier, M.D., Andrew A. Whelton, M.D., Mark T. Brown,

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

Implications of MDRD for Validity of Proteinuria as a Surrogate Endpoint.

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Trial profile Mann JF et al. Lancet 2008;372:

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Date of download: 5/29/2016 From: The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow- up of the Modification.

The RAVE Study Renal Athersosclerotic Revascularization Evaluation Reference Tobe SW, Atri M, Perkins N, et al. Renal Athersosclerotic revascularization.

Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.

Date of download: 7/1/2016 From: Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2015;162(4):

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

The SPRINT Research Group

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Baseline Characteristics of the Patients Part I

TNT: Baseline and final LDL cholesterol levels

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

The Hypertension in the Very Elderly Trial (HYVET)

Management of hypertension in patients with chronic kidney disease

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p = 0.32 for noninferiority)

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Enrollment and Outcomes

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Baseline Characteristics of the Subjects

Characteristics of the Patients at Baseline*

Flow of Patients Through Trial

Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation? Pantelis A. Sarafidis, Luis.

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

Baseline Characteristics of the Study Participants

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline Characteristics of the Subjects*

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Baseline Characteristics of the Patients – Part I

RECORD Study: Enrollment and Outcomes

The ACCORD Study Group. NEJM 2010; Epub March 14

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Baseline Characteristics of the Patients - Part I

Enrollment and Outcomes

Michael R. Lattanzio, Matthew R. Weir Kidney International

Volume 57, Pages S44-S48 (April 2000)

Dot plots comparing changes in renal function at pretreatment and after the first and last cycles in both hydration groups. Dot plots comparing changes.

Presentation transcript:

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:131-40

Baseline Characteristics of the Patients with Chronic Kidney Disease* Fan Fan Hou, et al. N Engl J Med 2006;354:131-40

Kaplan-Meier Estimates of the Percentage of Patients Not Reaching the Primary Composite End Point of a Doubling of the Serum Creatinine Level, End-Stage Renal Disease, or Death Fan Fan Hou, et al. N Engl J Med 2006;354:131-40

Use of Conventional Antihypertensive Medications at Baseline and during Study Treatment* Fan Fan Hou, et al. N Engl J Med 2006;354:131-40

Changes in Blood Pressure during Follow-up Fan Fan Hou, et al. N Engl J Med 2006;354:131-40

Changes in the Level of Proteinuria during Follow-up Fan Fan Hou, et al. N Engl J Med 2006;354:131-40

Changes in Creatinine Clearance during Follow-up Fan Fan Hou, et al. N Engl J Med 2006;354:131-40

Adverse Events after Randomization* Fan Fan Hou, et al. N Engl J Med 2006;354:131-40